Colostrinin™ Study Results

11/02/2008

ReGen Therapeutics Plc ('ReGen'or the 'Company') announces that its product Colostrinin™, which is currently marketed in the USA and Australia under the brand name CogniSure™, a nutritional supplement to 'support healthy brain aging and cognition in humans'* has recently been shown to be beneficial and well-tolerated in aging pet cats and dogs with signs of senility and/or cognitive dysfunction.

Open pilot studies, conducted by Cinque Ports Veterinary Associates, Hawkhurst, Kent, UK involved the daily dosing of aged cats and dogs with Colostrinin™ powder sprinkled into their food or drink.

To be eligible for the study, subject animals displayed acknowledged clinical signs of senility and/or cognitive dysfunction. Eighteen cats and twenty-two dogs, each resident in their normal domestic environment, received a daily dose of Colostrinin™ for four months. The clinical condition of each animal was assessed by a veterinary surgeon and the owner completed a questionnaire about aspects of the animal's behaviour at monthly intervals. Results were compared to individual base-line assessments, prior to treatment.

Summarising the study findings Nicholas Mills, Principal Investigator to the study said 'These results clearly show that Colostrinin™ can significantly reduce the symptoms of cognitive dysfunction in aged cats and dogs. That Colostrinin™ was effective was reinforced by the fact that when animals were assessed one month after completion of the study, and having had no Colostrinin™ for one month, most animals showed a worsened condition'.

The study showed Colostrinin™ to be well tolerated. With regard to specific benefits, a number of owners noted improvements in symptoms related to disorientation, sleep and grooming. A significant proportion of owners reported an increase in appetite, water consumption and an improvement in coat condition.

Percy Lomax, Chairman and Chief Executive Officer of ReGen said 'These results show a potential benefit for aging cats and dogs and we are entering into discussions with potential licensees. The full results are being written up with a view to publication in a peer-eviewed veterinary journal'.

More Colostrinin news:

Results of Study

31/03/2008

In-vivo study shows ReGen's ColostrininTM to be non-allergenic and able to prevent allergic inflammation.


ReGen Therapeutics Plc ('ReGen') is pleased to announce a report of a study conducted by Dr Istvan Boldogh* of the University of Texas Medical Branch was published on the 27 March on line in the International Archives of Allergy and Immunology. This study shows that ColostrininTM , ReGen's nutraceutical product, being marketed by Metagenics Inc., California for the 'support of healthy brain ageing and cognition', is not only non-allergenic, but prevents allergic inflammation due to common indoor and outdoor allergens.

Currently Metagenics and or its subsidiaries are selling ColostrininTM in Australasia since July 2007 and North America since October 2007. Headquartered in San Clemente, California, Metagenics is a leading developer, manufacturer and marketer of nutraceuticals, dedicated to researching and evaluating the effects of natural ingredients on genetic expression and protein activity. Additionally, on 25 March 2008 ReGen announced its first approval to launch in the European Union in Cyprus through Golgi Pharmaceuticals Ltd its distributor for that market.

Highlights of the study are as follows:


The objective of the study was to investigate potential allergic responses to ColostrininTM and its impact on allergic sensitisation and inflammation caused by common allergens to underpin its safe use as a human nutraceutical . A spray-dried whole Colostrum product which is commercially available as a nutraceutical was used as a control
The study used a well characterised mouse model of allergic airway inflammation
ColostrininTM (given orally, intranasally or intraperitoneally) significantly decreased IgE/IgG1 production, airway eosinophilia, mucin production and hypersensitivity induced by allergenic extracts from ragweed pollen and house dust mites
In contrast, Colostrum, from which ColostrininTM is derived, induced positive inflammatory responses
Commenting on these findings Dr. Marian Kruzel (a co-author of the publication and a scientific advisor to ReGen) said: ' These findings are entirely consistent with Colostrinin'sTM safety profile and use to support healthy cognition through significant reduction of reactive oxygen species (ROS) build up.'

Percy Lomax, Chairman and Chief Executive Officer added: 'The data shows that ColostrininTM may be used in humans without concern about experiencing an allergic reaction. This is in contrast to other less refined dairy-derived products, in particular whole colostrum, which is a significant US dietary product. We believe these findings will give impetus to the marketing of ColostrininTM.

A new article has been published in the latest Journal of Alzheimers Disease regarding Colostrinin (Cognisure)

You can buy this currently as a nutracetical, but they are developing a pharmaceutical version also.

-----------------------------------------

http://iospress.metapress.com/content/w07224q30717g012/?p=90d19f13669c41c286c9ff4b92315276&pi=1

Scientific Review published

25/04/2008

ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that a full review of the extensive science behind its product ColostrininTM, has been today published online in the Journal of Alzheimer's Disease.* This review states that when given orally ColostrininTM has been shown to have a stabilising effect on cognitive functions in improving the conditions of patients suffering from mild to moderate Alzheimer's disease. This review concludes that, whilst further extensive studies are required to understand the mechanism by which ColostrininTM exerts its biological effects, ColostrininTM clearly has potential benefit in the prevention and treatment of neurodegenerative disorders.

ColostrininTM is marketed in North America and Australia under the brand name CogniSureTM as a nutritional supplement to 'support healthy brain aging and cognition' in humans** and is available through the professional channel of healthcare practitioners such as chiropractors and doctors. The product is expected to be launched in the European Union in 2008.

Summarising this publication Dr. Marian Kruzel*** a co-author of the report said:

'This is a most comprehensive review regarding the potential utility of ColostrininTM in neurodegenerative disorders. It includes research into the novel mechanisms of action involved in neuroprotection and clearly presents Colostrinin'sTM biodiversity. This is the whole story of the potential of Colostrinin'sTM proactive function in age-associated mental capacity.'

Percy Lomax, Chairman and Chief Executive Officer of ReGen said:

'This review paper demonstrates the hard scientific evidence concerning the activity of ColostrininTM. This amount of scientific evidence is unusual for a nutraceutical and should support the further development of our marketing platform. We would also stress that this paper adds weight to our view of the likely potential of our ColostrininTM derived peptide programme to produce a pharmaceutical product that will be used in the treatment of neurodegenerative diseases.'

Just to mention that there is more about this in the Medications/treatments for Alzheimer's under the heading "Cognisure".

kind regards

Hi everyone,

News out today regardiing further reseach showing that Colostrinin/Cognisure helps with AD. You can already buy Cognisure as a nutraceutical, but this gives further hope to devloping a pharmaceutcal version too.



--------------------------------------------
New Study published

26/06/2008

Study showing that ReGen's Colostrinin™ protects hippocampal cells against beta-amyloid and oxidative stress is to be presented at the FENS Forum 2008

ReGen Therapeutics Plc ('ReGen' or 'the Company') announces the publication of a new study showing that ReGen's Colostrinin™ protects hippocampal cells against beta-amyloid and oxidative stress. The research, which has been performed by ReGen's collaborators at the Open University, Milton Keynes, United Kingdom is to be presented as a poster at the FENS Forum 2008*, Geneva on 16 July 2008.

It has previously been shown that Colostrinin™ can prevent beta-amyloid induced impairment of learning in newly hatched chicks [1] and can protect standardised laboratory neurological cells against beta-amyloid induced toxicity and oxidative stress induced damage [2]. However, the research presented at the FENS Forum is the first study to show these effects on isolated hippocampal cells.

Commenting on the study, Professor Mike Stewart the senior investigator and scientific advisor to ReGen said

'These findings are very significant as the hippocampus is one of the key brain areas known to be affected in neurodegenerative diseases such as Alzheimer's disease. It is of particular importance to note that Colostrinin™ can directly protect these neurons that have such an important role in cognition and memory'.

Percy Lomax, Chairman and Chief Executive of ReGen said

'This research gives us further confidence in promoting Colostrinin™/CogniSure™ as a nutraceutical for healthy brain ageing. Longer term it adds to our belief that our peptide programme may be able to produce a pharmaceutical product with utility in Alzheimer's disease and other similar neurological disease conditions'.

A copy of the full abstract is available at:

http://fens2008.neurosciences.asso.fr/pages/posters_sessions.html

(Poster session 7 - Wednesday, July 16, 09:30-13:00, Section P217 - C: Alzheimer's 4). Froud K., Saffrey M. J., Stewart M. G., Banks D. & Wardhaugh T.

* The FENS Forum is the premier European Neuroscience meeting of 2008

1. Boldogh, I, Kruzel, M. L Journal of Alzheimer's Disease 13 (2008) 303-321
2. Banks D, Stewart M. G. Soc Neurosci Abstr proceedings (2006) 674.5